FLAG regimen
|
WikiDoc Resources for FLAG regimen |
|
Articles |
|---|
|
Most recent articles on FLAG regimen Most cited articles on FLAG regimen |
|
Media |
|
Powerpoint slides on FLAG regimen |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on FLAG regimen at Clinical Trials.gov Clinical Trials on FLAG regimen at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on FLAG regimen
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on FLAG regimen Discussion groups on FLAG regimen Patient Handouts on FLAG regimen Directions to Hospitals Treating FLAG regimen Risk calculators and risk factors for FLAG regimen
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for FLAG regimen |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Overview
FLAG regimen refers to a regimen consisting of fludarabine, high-dose cytarabine (AraC) and filgrastim (G-CSF), used as a remission-induction treatment for relapsed or refractory childhood acute myeloid leukemia (AML)[1]
Regimen
FLFludarabine
ACytarabine (AraC)
GFilgrastim (G-CSF)
Indications
- Relapsed or refractory childhood acute myeloid leukemia (AML)[1]
References
- ↑ 1.0 1.1 Montillo M, Mirto S, Petti MC, Latagliata R, Magrin S, Pinto A; et al. (1998). "Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia". Am J Hematol. 58 (2): 105–9. PMID 9625576.